NCT03049462View on ClinicalTrials.gov

The Physiological Responses and Adaptation of Brown Adipose Tissue to Chronic Treatment With Beta3-Adrenergic Receptor Agonists

PHASE1RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

March 13, 2017

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2026

Conditions
Polycystic Ovary Syndrome
Interventions
DRUG

Mirabegron

Women will take 100mg daily for 4 weeks. Men will take 200mg daily for 4 weeks. The medication is available in 50 mg tablets.

OTHER

B Complex Plus Vitamin C Tablets

Males will be randomized to take placebo versus active drug (mirabegron). Those taking placebo will take 4 tablets each day to mirror to active group (taking 4 tablets of 50 mg each).

Trial Locations (1)

20892

RECRUITING

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH